BTIG analyst Mark Massaro raised the firm’s price target on MDxHealth to $8 from $7 and keeps a Buy rating on the shares after its Q4 results. The company executed nearly flawlessly operationally in 2023 and announced it is evaluating a number of growth opportunities in the form of new partnerships or possible acquisitions, the analyst tells investors in a research note. MDx Health is an attractive small-cap growth and value stock, positioned as a “one-stop-shop in prostate diagnostics testing”, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDXH:
- Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results
- Is MDXH a Buy, Before Earnings?
- MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6
- MDxHealth director Jan Pensaert resigns
- MDxHealth Sees FY23 revenue $70.2M, consensus $69.15M
